Document resource
Orforglipron, a new glucagon-like peptide-1 (GLP-1) receptor agonist pill, leads to greater glycaemic control and weight loss for patients with type 2 diabetes than oral semaglutide (Rybelsus), researchers have reported.1
Annotated abstract
New weight loss pill outperforms oral semaglutide for diabetes patients, study reports
bmj · 2026-02-27 · canonical JSON source